UnitedHealth Group reported a 4Q revenue increase of 12% year-over-year to $113.2 billion, narrowly missing consensus estimates, while adjusted EPS plunged from $6.81 to $2.11. The miss reflected elevated medical cost trends and reserve build-ups in its UnitedHealthcare segment, compounded by a government proposal to hold Medicare Advantage reimbursement rates flat for 2027. This regulatory development exacerbated investor concerns over margin compression and triggered a near-20% one-day market value decline.

Despite these headwinds, valuation metrics suggest UNH is trading well below its historical averages on both price/free-cash-flow and P/E bases. A conservative discounted cash flow model, assuming a 6% terminal growth rate and 8% discount rate, yields intrinsic value estimates 15% higher than current levels; a more optimistic DCF, with a 7% terminal growth rate, implies upside closer to 25%. Relative to peers, UnitedHealth’s forward EV/EBITDA multiple sits in the bottom decile of the last decade, indicating that most adverse scenarios appear fully priced in.

Management has characterized 2026 as a transitional period, guiding to adjusted EPS slightly above $17.75 and revenue of just over $439 billion. The company is prioritizing a return to a 5.5% EBIT margin in UnitedHealthcare through targeted cost controls and expects to deliver $1 billion in annualized operating expense savings via AI-driven automation in claims processing and care management. While membership growth will be modest given regulatory uncertainty, executives reiterated confidence in long-term double-digit free-cash-flow expansion, underpinning dividend growth and share repurchase capacity.